期刊
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 22, 期 6, 页码 1091-1101出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1871520621666210608110435
关键词
Brefeldin A; chronic myelogenous leukemia; BCR-ABL; degradation; caspase; K562 cells
资金
- National Key Research and Development Program of China [2017YFE0195000]
- National Natural Science Foundation of China [81872792, 41676127, U1706210, 41776141]
- Fundamental Research Funds for the Central Universities [201841004]
- Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao) [2018SDKJ0403-2]
- Taishan Scholars Program, China [tsqn20161010]
In this study, we found that Brefeldin A (BFA) is a cytotoxic compound that inhibits the activation of BCR-ABL and degrades the BCR-ABL protein in K562 cells, thereby suppressing the development of CML.
Background: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease caused by BCR-ABL oncoprotein. Tyrosine kinase inhibitors have been developed to inhibit the activity of BCR-ABL; however, drug resistance and side effect occur in clinic application. Therefore, it is urgent to find novel drugs for CML treatment. Under the guidance of cytotoxic activity, crude extracts of 55 fungal strains from the medicinal mangrove Acanthus ilicifolius were evaluated, and one potent cytotoxic natural compound, brefeldin A (BFA), was discovered from Penicillium sp. (HS-N-29). Objective: This study was aimed to determine the cytotoxic activity of BFA and the effect on the activation and expression of BCR-ABL in K562 cells. Methods: We evaluated cytotoxic activity by MTT assay and soft agar clone assay; apoptosis and cell cycle distribution by Muse cell analyzer. The protein level of BCR-ABL and signaling molecules was detected by western blotting, and the mRNA level of BCR-ABL was determined by RT-PCR. Results: BFA inhibited cell proliferation, induced G2/M cell cycle arrest, and stimulated cell apoptosis in K562 cells. Importantly, for the first time, we revealed that BFA inhibited the activation of BCR-ABL and consequently inhibited the activation of its downstream signaling molecules in K562 cells. Moreover, we found BFA degraded BCR-ABL without affecting its transcription in K562 cells, and BFA-induced BCR-ABL degradation was related to caspase activation, while not to autophagy or ubiquitinated proteasome degradation pathway. Conclusion: Our present results indicate that BFA acts as a dual functional inhibitor and degrader of BCR-ABL, and BFA is a potential compound for chemotherapeutics to overcome CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据